|View printer-friendly version|
BeyondSpring’s Lead Asset, Plinabulin, Granted U.S. Patent Covering Methods of Treating Brain Tumors
The patent, which expires in 2036, covers methods for Plinabulin’s use in the treatment of brain tumors, including metastatic brain tumor, with no approved chemotherapy on the market, and glioblastoma multiforme (GBM), the most common adult brain tumor. Both are known for their lethality and lack of response to treatment using the current standard of care. Dr.
Only surgery and radiation, but no chemotherapy had ever been granted in metastatic brain tumor, with survival at around 4 to 6 months. Without the current advancement in primary tumor treatment, more patients would develop metastatic brain tumor with grim outcome. In recent years, there have been no substantial improvements in treatment options, and minimal improvements in the survival prospects for patients with GBM. The average life expectancy for GBM after symptoms onset is approximately 6 to 12 months.
“The cancer-fighting properties of Plinabulin, either alone or combined with other compounds, continues to show promise as our clinical trials show beneficial outcomes in a myriad of cancers,” said Dr. Huang. “When it comes to brain cancer, there remains an urgent need for improved treatments, as most of the current treatment methods – like chemotherapy – have limitations as they cannot penetrate the blood-brain barrier on their own. We are pleased with the long runway of Plinabulin patents, including a composition of matter patent directed to Plinabulin monohydrate crystalline form, which currently expires in 2036. Currently we have 74 granted patents in 36 jurisdictions globally and 17 patents granted in the U.S. directed to Plinabulin and Plinabulin analogs, their synthesis, and their use in the treatment of various disorders.”
Plinabulin is currently in Phase 3 global clinical development for the treatment of non-small cell lung cancer (NSCLC) and for the prevention of chemotherapy-induced neutropenia (CIN).
Cautionary Note Regarding Forward-Looking Statements
Source: BeyondSpring, Inc.